Vaccination Against Human Papillomavirus Decreases Related Tests and Treatment for Cervical Cancer(6/3/2008) Researchers affiliated with the Quadrivalent HPV Vaccine Merck Study Group have reported that vaccination against human papillomavirus (HPV) is associated with a reduction in Pap tests, colposcopy, cervical biopsy, and definitive treatment among women who were uninfected at the time of vaccination. The details of this study were presented at the 39th annual meeting of the Society of Gynecologic Oncologists (SGO) in Tampa, Florida, from March 9 to 12, 2008.
African Americans with First-degree Relatives with Colon Cancer Have Poor Screening Rate(3/27/2008) Researchers from Vanderbilt University have reported that 27% of African Americans with a first-degree relative with colon cancer undergo screening colonoscopy compared with 43% for White persons. The details of this study appeared in the March 24, 2008 issue of the Archives of Internal Medicine.
Increased Risk of Cancer Persists Long after Treatment for Precancerous Cervical Changes(11/9/2007) Researchers from Sweden have reported that women who have been treated for high-grade precancerous changes to the cervix (cervical intraepithelial neoplasia grade 3) are more likely than women in the general population to subsequently develop cervical or vaginal cancer. Furthermore, this increased risk persists for at least 25 years. The details of this study appeared in an early on-line publication in the British Medical Journal on October 24, 2007.
HPV Testing Superior to Papanicolaou Testing for Cervical Cancer Screening(11/3/2007) Two recent studies published in the October 18, 2007 issue of the New England Journal of Medicine help clarify the effects of screening for human papillomavirus (HPV) compared to standard Papanicolaou (Pap) testing.
Cervarix™, a Vaccine against HPV 16/18 Effective for Cervical Cancer Prevention(7/2/2007) Researchers involved in the PATRICIA study (Papilloma Trial against Cancer in Young Adults) have reported that the adjuvanted human papilloma virus (HPV) vaccine Cervarix (GlaxoSmithKline) was 90.4% effective in preventing cervical intraepithelial neoplasia (CIN) 2+ related to HPV16/18 in previously unexposed women. The details of this study were published in the June 30, 2007 issue of The Lancet.
HPV Vaccine, Cervarix™, not Therapeutic in Women with Preexisting Infection(8/22/2007) Researchers affiliated with the Costa Rican HPV Vaccine Trial have reported that women who are positive for HPV DNA, do not benefit from Cervarix (GlaxoSmithKline) a vaccine against HPV 16/18 L1 virus-like particle. The details of this study appeared in the August 15, 2007 issue of the Journal of the AmericanMedical Association.
Progress on Development of Vaccines to Prevent and Treat HPV Associated Cervical Cancer(5/2/2003) In a conference titled
Development of Therapeutic Cancer Vaccines held in Los Angeles on April 27-29, 2003, Ian Fraxer from Brisbane, Australia reviewed the progress of efforts to develop vaccines against human papilloma (HPV) for prevention of infection, prevention of cervical cancer, and for therapy of established cervical cancer
Stages II-IVA
Progress on Development of Vaccines to Prevent and Treat HPV Associated Cervical Cancer(5/2/2003) In a conference titled
Development of Therapeutic Cancer Vaccines held in Los Angeles on April 27-29, 2003, Ian Fraxer from Brisbane, Australia reviewed the progress of efforts to develop vaccines against human papilloma (HPV) for prevention of infection, prevention of cervical cancer, and for therapy of established cervical cancer
Metastatic / Stage IVB
Recurrent
Neulasta® on First Day of Chemotherapy May Be More Convenient for Gynecologic Cancers(3/18/2008) Researchers from the University of Alabama have reported that the administration of Neulasta® (pegfilgrastim) on the first day of chemotherapy among women with gynecologic cancers may be as effective as and more convenient than second-day administration. These results were recently reported at the 2008 annual Society of Gynecologic Oncologists meeting.
Avastin® Combination Has Activity in Heavily Pretreated Cervical Cancer(11/13/2006) Researchers from Washington University have reported that Avastin (bevacizumab) in combination with 5-FU or Xeloda® (capecitabine) is active in women with heavily pretreated, recurrent cervical cancer.
Progress Reported on Human Papilloma Virus (HPV) Vaccine(4/30/2003) Dr. John Neefe, from Stress Biotechnologies, reported progress on CoVal™, a Human Papilloma Virus vaccine at a conference titled
Development of Therapeutic cancer Vaccines held in Los Angeles April 27-29. This meeting was sponsored by the John Wayne Cancer Institute, the International Association of Biologicals, and the Royal Society of Medicine.
Patient Home
